2026 Frontline Multiple Myeloma Treatment Guide: Quadruplet Standards, Fitness Stratification, and Frailty-Adapted Pathways

Foreword: Key Takeaways

"I was just diagnosed with multiple myeloma—what is the most effective initial treatment?" "Will I need a stem cell transplant?" "How do doctors choose between four-drug regimens, three-drug regimens, and steroid-sparing options?"

In multiple myeloma, the frontline (first-line) therapy represents the single most critical window of opportunity. The depth and durability of your initial response directly dictate long-term progression-free survival (PFS) and overall quality of life:

1. The 2026 Quadruplet Standard of Care: Frontline therapy has officially shifted to four-drug combinations adding an anti-CD38 monoclonal antibody (daratumumab or isatuximab) to a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and dexamethasone (e.g., Dara-VRd, Isa-VRd, Isa-KRd).
2. Biological Fitness Dictates Transplant Eligibility: Chronological age alone does not determine transplant eligibility. Comprehensive geriatric assessments (such as the IMWG Frailty Score) stratify patients into Fit, Intermediate-Fit, and Frail categories to personalize therapy intensity.
3. Transformative Frontline Options for Older and Frail Patients: For transplant-ineligible patients, continuous Dara-Rd (MAIA trial) delivers a median PFS exceeding 5.1 years, while novel steroid-sparing strategies (IFM2017-03: Dara-R with only 2 cycles of dexamethasone) dramatically reduce toxicities without compromising survival.

1. Diagnostic and Fitness Stratification in Newly Diagnosed Myeloma

Accurate diagnosis, genomic risk profiling, and fitness evaluations are essential prior to initiating frontline therapy.

Clinical Diagnostic & Triage Pathway

• Stage 1: Diagnosis Confirmation (SLiM-CRAB):

  • Clonal bone marrow plasma cells ≥ 10% (or biopsy-proven plasmacytoma) PLUS at least one SLiM or CRAB myeloma-defining feature.
• Stage 2: Biological Fitness Assessment (IMWG Frailty Score):

  • Evaluates chronological age, comorbidities (Charlson Comorbidity Index), and functional independence (ADL & IADL).
• Stage 3: Stratified Frontline Pathways:

  • Fit (Score = 0): Full-dose quadruplet induction (Dara-VRd / Isa-VRd) → ASCT → Quadruplet consolidation → Risk-adapted maintenance.
  • Intermediate-Fit (Score = 1): Modified quadruplet (Dara-VRd with weekly bortezomib) or continuous Dara-Rd.
  • Frail (Score ≥ 2): Continuous Dara-Rd or upfront steroid-sparing Dara-R (2 cycles dexamethasone).

1.1 The IMWG SLiM-CRAB Diagnostic Criteria

To prevent irreversible organ damage, the International Myeloma Working Group (IMWG) established that active, treatable multiple myeloma requires ≥ 10% clonal bone marrow plasma cells (or a biopsy-proven plasmacytoma) along with at least one SLiM-CRAB myeloma-defining event:

1.2 IMS-IMWG 2024 High-Risk Cytogenetic Consensus

All newly diagnosed patients must undergo baseline interphase fluorescence in situ hybridization (iFISH) on CD138-purified bone marrow plasma cells. Under the IMS-IMWG 2024 Consensus, ultra-high-risk myeloma is defined by:

• del(17p) (with a cancer clonal fraction ≥ 20%) and/or a TP53 mutation (by NGS).
• t(4;14), t(14;16), or t(14;20) co-occurring with +1q (gain [3 copies] or amplification [≥ 4 copies]) and/or del(1p32).
• Monoallelic del(1p32) co-occurring with 1q gain, or biallelic del(1p32).
• High β₂-microglobulin (> 5.5 mg/dL) in the presence of normal renal function (serum creatinine < 1.2 mg/dL).

1.3 Fitness and Frailty Stratification (The IMWG Frailty Score)

Transplant candidacy is guided by biological fitness rather than chronological age. The IMWG Frailty Score (FS) evaluates:

1. Age: < 75 (0 pts), 75–80 (1 pt), > 80 (2 pts).
2. Comorbidities: Charlson Comorbidity Index (CCI ≤ 1 = 0 pts; CCI ≥ 2 = 1 pt).
3. Functional Status: Activities of Daily Living (ADL > 4 = 0 pts; ADL ≤ 4 = 1 pt) and Instrumental ADL (IADL > 5 = 0 pts; IADL ≤ 5 = 1 pt).

• Fit (Score = 0): Eligible for full-dose quadruplet induction followed by autologous stem cell transplantation (ASCT).
• Intermediate-Fit (Score = 1): Eligible for modified triplets/quadruplets (e.g., Dara-VRd with weekly bortezomib or VRd-Lite).
• Frail (Score ≥ 2): High risk of treatment-related toxicity; ASCT is not recommended. Continuous Dara-Rd or steroid-sparing Dara-R is the standard of care.

Literature References: IMWG SLiM-CRAB Criteria (Lancet Oncol 2014); IMS-IMWG High-Risk Consensus (Blood 2024); IMWG Frailty Score (Blood 2015)

2. Transplant-Eligible (TE-NDMM): The Quadruplet + ASCT Continuum

For transplant-eligible patients, the standard frontline pathway consists of 4 cycles of quadruplet induction → ASCT consolidation → 2 cycles of quadruplet consolidation → tailored maintenance therapy.

Four-Phase Treatment Continuum:

1. Phase 1: Quadruplet Induction (4 Cycles) — Dara-VRd or Isa-VRd to rapidly eliminate cancer cells and clear the bone marrow.
2. Phase 2: Stem Cell Collection & High-Dose Melphalan ASCT — Stem cell mobilization followed by Melphalan 200 mg/m² to reset the bone marrow.
3. Phase 3: Quadruplet Consolidation (2 Cycles) — Deepens remission and converts partial responses into complete MRD negativity.
4. Phase 4: Risk-Adapted Maintenance — Standard risk: Dara-R or Lenalidomide monotherapy; High risk: Dual VR / KR / Dara-R.

2.1 Quadruplet Induction Evidence

• Dara-VRd (PERSEUS Phase 3 Trial):

  • Subcutaneous daratumumab + VRd induction/consolidation followed by Dara-R maintenance vs. VRd followed by R maintenance.
  • 4-Year Progression-Free Survival (PFS): 84.3% with Dara-VRd vs. 67.7% with VRd (HR = 0.42, 95% CI: 0.30–0.59; P < 0.001), reducing progression or death risk by 58%.
  • Depth of Response: ≥ CR rate was 87.9% vs. 70.1%; bone marrow MRD negativity (10⁻⁵) was 75.2% vs. 47.5%; ultra-deep MRD negativity (10⁻⁶) was 65.1% vs. 32.2% (P < 0.001).
  • Sustained MRD Negativity (≥ 12 months): Reached 64.8% with Dara-VRd vs. 29.7% with VRd (OR = 4.42, P < 0.0001).
• Isa-VRd (GMMG-HD7 Phase 3 Trial):

  • Isatuximab + VRd induction demonstrated a post-transplant 10⁻⁵ MRD-negativity rate of 66% vs. 48% with VRd, translating into superior PFS (HR = 0.70, P = 0.018).
• Isa-KRd & Dara-KRd (IsKia & MANHATTAN Trials):

  • In the phase 3 IsKia trial, Isa-KRd consolidation achieved a 10⁻⁶ ultra-deep MRD-negativity rate of 67% vs. 48% with KRd (OR = 2.29, P < 0.001), including 72% in high-risk patients.
  • In the MANHATTAN study, Dara-KRd induction without immediate transplant achieved a 1-year PFS of 98% and 1-year OS of 100%.

2.2 Stem Cell Mobilization and High-Dose Melphalan (Mel200) ASCT

1. Mobilization Protocol: Initiated after 4 cycles of induction using G-CSF (10 μg/kg/day) ± Plerixafor (Mozobil 240 μg/kg). Target yield: ≥ 4.0–6.0 × 10⁶ CD34+ cells/kg, allowing sufficient stem cells for both primary ASCT and potential future salvage ASCT.
2. Conditioning Regimen: High-Dose Melphalan (200 mg/m² IV) administered on Day -2 or Day -1. In patients with severe renal impairment (CrCl < 30 mL/min), melphalan is dose-reduced to 140 mg/m².

2.3 Post-Transplant Maintenance and MRD-Guided De-escalation

• Standard-Risk Maintenance:

  • Lenalidomide monotherapy (10 mg/day) remains a proven standard backbone.
  • Dara-R Maintenance (AURIGA Trial): In post-ASCT MRD-positive patients, adding daratumumab to lenalidomide increased the 12-month MRD-negativity conversion rate to 50.5% vs. 18.8% (OR = 4.51, P < 0.0001), improving 30-month PFS to 82.7% vs. 66.4%.
  • PERSEUS Protocol-Defined De-escalation: Patients on Dara-R maintenance who achieve ≥ CR and maintain sustained 10⁻⁵ MRD negativity for ≥ 12 months (after ≥ 24 months of maintenance) discontinue daratumumab and continue on lenalidomide alone, reducing treatment burden and toxicity.
• High-Risk Maintenance:

  • Patients with high-risk cytogenetics benefit from dual-agent maintenance (e.g., Bortezomib + Lenalidomide [VR], Carfilzomib + Lenalidomide [KR], or Dara-R) to prevent early disease recurrence.

Literature References: PERSEUS (NEJM 2024), GMMG-HD7 (Lancet Oncol 2024), IsKia (Lancet Oncol 2024), AURIGA (Blood 2024)

3. Transplant-Ineligible (TNE-NDMM) and Frailty-Adapted Pathways

For patients ineligible for transplantation due to age or frailty, modern therapy focuses on maximizing depth of response while preserving functional independence.

Stratified Pathways for Non-Transplant Patients:

• Option A: Non-Frail / Intermediate-Fit (Age < 80, Good PS):

  • Dara-VRd (CEPHEUS Trial): 54-Month PFS 68.1% and 60.9% 10⁻⁵ MRD negativity.
  • Continuous Dara-Rd (MAIA Trial): Proven 5-year overall survival benchmark.
• Option B: Frail / Vulnerable / Age ≥ 80 (Frailty Score ≥ 2):

  • Continuous Dara-Rd (MAIA Trial): Median PFS 61.9 months with manageable oral/SC scheduling.
• Option C: Severe Steroid Intolerance / High Infection Risk:

  • Dex-Sparing Dara-R (IFM2017-03 Trial): Only 2 initial cycles of dexamethasone; median PFS 53.4 months (HR = 0.51).

3.1 Continuous Dara-Rd (The MAIA Benchmark)

The phase 3 MAIA trial established Daratumumab + Lenalidomide + Dexamethasone (Dara-Rd) as the global standard of care for transplant-ineligible patients:

• Median Progression-Free Survival (PFS): 61.9 months (over 5.1 years) with Dara-Rd vs. 34.4 months with Rd (HR = 0.55, 95% CI: 0.45–0.67; P < 0.0001).
• Overall Survival (OS): Median OS was Not Reached with Dara-Rd vs. 65.5 months with Rd (HR = 0.66, P = 0.0003); 5-year OS rate was 66.6% vs. 53.6%.
• Dynamic Response Deepening: 10⁻⁵ bone marrow MRD negativity rose from 12.8% at 12 months to 31.8% at 60 months, demonstrating that continuous antibody therapy steadily clears malignant clones.
• Efficacy in Octogenarians (≥ 80 years): Delivered consistent survival advantages (PFS HR = 0.48, P = 0.0011).

3.2 Dara-VRd in Transplant-Ineligible/Deferred Patients (CEPHEUS Trial)

The phase 3 CEPHEUS trial evaluated D-VRd vs. VRd in non-frail, transplant-ineligible or deferred patients:

• 54-Month PFS: 68.1% with D-VRd vs. 49.5% with VRd (HR = 0.57, P = 0.0005).
• MRD Negativity (10⁻⁵): 60.9% vs. 39.4% (OR = 2.37, P < 0.0001); sustained MRD negativity (≥ 12 months) was 48.7% vs. 26.3%.
• Clinical Guidance: Because Grade ≥ 2 peripheral neuropathy occurred in ~39% of patients, weekly subcutaneous bortezomib must be utilized.

3.3 The Dexamethasone-Sparing Strategy (IFM2017-03 Trial)

Prolonged corticosteroid use causes significant morbidity in older adults (severe insomnia, muscle wasting, mood disturbances, glucose instability, and opportunistic infections).

Literature References: MAIA (NEJM 2019, Lancet Oncol 2021); CEPHEUS (Nature Medicine 2025); IFM2017-03 (Lancet Oncol 2024)

4. Master Clinical Trial Benchmark: Frontline Regimens

5. Frontline Innovations: Cellular Immunotherapy Upfront

Investigative trials are evaluating CAR T-cell therapies in frontline settings to achieve ultra-deep remissions without traditional high-dose cytotoxic conditioning:

• AZD0120 (GC012F BCMA/CD19 Dual-Targeting FasTCAR):

  • Evaluated as frontline consolidation following only 2 cycles of RVd induction in 30 newly diagnosed patients (48% high-risk cytogenetics).
  • Overall Response Rate (ORR): 100%, with a 97% stringent complete response (sCR) rate.
  • Depth of Clearance: 100% of patients achieved bone marrow MRD negativity at the ultra-deep 10⁻⁶ threshold by EuroFlow (81.5% sustained > 12 months).
  • Survival: 30-month PFS and OS rates were 88% and 92%, respectively, with zero difference between high-risk and standard-risk patients.
  • Safety: 33% Grade 1–2 CRS; 0% Grade ≥ 3 CRS and 0% ICANS.
• Equecabtagene Autoleucel (FUMANBA-2 Trial):

  • In 16 high-risk NDMM patients, frontline eque-cel achieved a 100% ORR, 93.8% sCR rate, and 100% 10⁻⁵ MRD-negativity rate, with 24-month PFS of 74.5%.

6. Comprehensive Supportive Care Standards

Achieving optimal outcomes requires rigorous supportive care to protect vital organs and prevent treatment-related complications.

6.1 Bone-Modifying Agents (BMAs)

• Indication: Recommended for all patients with active multiple myeloma regardless of visible osteolytic lesions.
• Zoledronic Acid (4 mg IV every 3–4 weeks): Standard therapy; requires dose adjustments for renal impairment.
• Denosumab (120 mg SC every 4 weeks): Preferred in patients with renal insufficiency (CrCl < 30 mL/min), as it is cleared via the reticuloendothelial system and does not cause nephrotoxicity.
• Mandatory Precaution: Routine baseline dental clearance prior to initiation to prevent Osteonecrosis of the Jaw (ONJ); concurrent daily calcium (500 mg) and Vitamin D (400–800 IU) supplementation.

6.2 Thromboprophylaxis

Regimens combining IMiDs (lenalidomide/thalidomide) with dexamethasone carry a significant risk of venous thromboembolism (VTE).

• Calculate baseline risk using the IMPEDE VTE or SAVED scoring systems.
• Standard Risk (Score < 3): Aspirin (81–100 mg/day).
• High Risk (Score ≥ 3 or history of VTE / central venous catheter): Prophylactic Low-Molecular-Weight Heparin (Enoxaparin 40 mg SC daily) or therapeutic Direct Oral Anticoagulants (DOACs: Apixaban 2.5 mg BID or Rivaroxaban 10 mg daily).

6.3 Infection Prophylaxis

• Herpes Zoster Prophylaxis: Acyclovir (400 mg PO BID) or Valacyclovir (500 mg PO daily) is mandatory for all patients receiving proteasome inhibitors (bortezomib, carfilzomib) or anti-CD38 antibodies, continuing for at least 3 months post-therapy.
• PJP Prophylaxis: Trimethoprim-sulfamethoxazole (TMP-SMX 1 DS tab 3x/week) during high-dose steroid therapy, post-ASCT, or cellular therapy.
• Antibacterial Prophylaxis: Prophylactic fluoroquinolones (levofloxacin) during the initial 3 months of therapy or during severe neutropenia.
• IVIG Substitution: Monthly IVIG (400 mg/kg) if serum IgG < 4.0 g/L in patients experiencing recurrent bacterial sinopulmonary infections.

6.4 Peripheral Neuropathy (PN) Mitigation

• Mandatory Subcutaneous (SC) Bortezomib: Administering bortezomib subcutaneously (rather than IV) reduces Grade ≥ 3 PN from 16% to 6%.
• Weekly Scheduling: Transition from twice-weekly to once-weekly bortezomib dosing in older or intermediate-fitness populations.

Conclusion: Setting the Foundation for Long-Term Survivorship

1. Aim for Deep Clearance from Day One: The frontline setting is your best opportunity to achieve sustained MRD negativity, which directly correlates with long-term survival.
2. Embrace Modern Quadruplets: If transplant-eligible, prioritize 4-drug regimens (Dara-VRd, Isa-VRd, or Isa-KRd) supported by global phase 3 evidence.
3. Personalize Therapy Based on Fitness: If older or managing comorbidities, continuous Dara-Rd or steroid-sparing Dara-R provides long-term disease control with manageable toxicity.
4. Prioritize Proactive Supportive Care: Adhere strictly to bone-strengthening, blood clot prevention, and antiviral regimens to safeguard your quality of life.

Multiple myeloma therapy in 2026 is precise, powerful, and increasingly personalized. Partnering closely with your hematology team ensures that you receive a customized frontline regimen designed for long-term health and vitality.

This clinical education guide is compiled by the China Myeloma Development Network (CMDN - ChinaMyeloma.org) based on peer-reviewed literature, international clinical practice guidelines, and phase 3 trial evidence. It is intended for educational purposes only and does not constitute formal medical advice. Please consult your treating hematologist or oncology team for individual clinical decision-making.